GlobeNewswire Inc.··NaEditas Medicine Slashes Q4 Losses While Advancing CRISPR Therapy Toward Human Trials
Editas Medicine reported Q4 2025 net loss of $5.6M, down 88% YoY. Lead CRISPR therapy EDIT-401 shows >90% LDL-C reduction; IND submission expected mid-2026.
BMYCELGrEDITclinical trialCRISPR